BOLD NASDAQ
Boundless Bio, Inc.
1W: -1.5%
1M: -9.3%
3M: +4.8%
YTD: +114.8%
1Y: +113.0%
$2.62
+0.03 (+1.16%)
Weekly Expected Move ±4.7%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (19)
Beam alleges Chinese biotech, and its U.S. partner Serapha stole trade secrets
21shares and FTSE Russell Announce Global Benchmark Partnership Across US, European, and Australian ETP Suites
21Shares AG (the “Issuer”) Extension of Partial Fee Waiver for Exchange Traded Products
These Emerging Companies Are Racing Toward Major Catalysts
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio GAAP EPS of -$0.60
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
Boundless Bio GAAP EPS of -$0.58 misses by $0.12
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference